IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 373 
Small font sizeDefault font sizeIncrease font size
Read this article

 


    Article Cited by others

LETTER TO THE EDITOR

Bedaquiline: A new drug approved for treatment of multidrug-resistant tuberculosis

Deoghare Shashank

Year : 2013| Volume: 45| Issue : 5 | Page no: 536-537

   This article has been cited by
 
1 Recent developments, challenges and future prospects in advanced drug delivery systems in the management of tuberculosis
Nitin Verma, Vimal Arora, Rajendra Awasthi, Yinghan Chan, Niraj Kumar Jha, Komal Thapa, Talha Jawaid, Mehnaz Kamal, Gaurav Gupta, Gang Liu, Keshav Raj Paudel, Philip Michael Hansbro, Brian Gregory George Oliver, Sachin Kumar Singh, Dinesh Kumar Chellappan, Harish Dureja, Kamal Dua
Journal of Drug Delivery Science and Technology. 2022; : 103690
[Pubmed]  [Google Scholar] [DOI]
2 Emerging strategies in nanotechnology to treat respiratory tract infections: realizing current trends for future clinical perspectives
Minhua Chen, Zhangxuan Shou, Xue Jin, Yingjun Chen
Drug Delivery. 2022; 29(1): 2442
[Pubmed]  [Google Scholar] [DOI]
3 The respiratory lipoquinone, menaquinone, functions as an inducer of genes regulated by the Mycobacterium smegmatis repressor MSMEG_2295
Anik Barman, Madhu Manti Patra, Sujoy K. Das Gupta
Microbiology . 2022; 168(5)
[Pubmed]  [Google Scholar] [DOI]
4 Nontuberculous Mycobacterial Resistance to Antibiotics and Disinfectants: Challenges Still Ahead
Samira Tarashi, Seyed Davar Siadat, Abolfazl Fateh, Fu-Ming Tsai
BioMed Research International. 2022; 2022: 1
[Pubmed]  [Google Scholar] [DOI]
5 Discovery and Development of Antibacterial Agents: Fortuitous and Designed
Ravleen Kaur, Pooja Rani, Atanas G. Atanasov, Qushmua Alzahrani, Reena Gupta, Bhupinder Kapoor, Monica Gulati, Pooja Chawla
Mini-Reviews in Medicinal Chemistry. 2022; 22(7): 984
[Pubmed]  [Google Scholar] [DOI]
6 Hit Compounds and Associated Targets in Intracellular Mycobacterium tuberculosis
Clement K. M. Tsui, Flavia Sorrentino, Gagandeep Narula, Alfonso Mendoza-Losana, Ruben Gonzalez del Rio, Esther Pérez Herrán, Abraham Lopez, Adama Bojang, Xingji Zheng, Modesto Jesus Remuiñán-Blanco, Yossef Av-Gay
Molecules. 2022; 27(14): 4446
[Pubmed]  [Google Scholar] [DOI]
7 AN INSIGHT INTO PRIVILEGED SCAFFOLDS IN TUBERCULOSIS: DEVELOPMENTAL ASPECTS AND IMPLICATIONS IN DRUG DESIGN
Rani. A. Shinde, Vasanti. M. Suvarna, Arundhati. N. Abhyankar
Indian Drugs. 2022; 59(01): 7
[Pubmed]  [Google Scholar] [DOI]
8 Impact of drug-resistant tuberculosis treatment on hearing function in South African adults: Bedaquiline versus kanamycin
Katijah Khoza-Shangase, Marina Prodromos
South African Journal of Communication Disorders. 2021; 68(1)
[Pubmed]  [Google Scholar] [DOI]
9 An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004–2018)
Mahanjit Konwar, MiteshR Maurya, TusharB Nishandar, UrmilaM Thatte, NithyaJ Gogtay
Perspectives in Clinical Research. 2021; 12(3): 159
[Pubmed]  [Google Scholar] [DOI]
10 A review of current and promising nontuberculous mycobacteria antibiotics
Christophe R Cantelli, Alexandra Dassonville-Klimpt, Pascal Sonnet
Future Medicinal Chemistry. 2021; 13(16): 1367
[Pubmed]  [Google Scholar] [DOI]
11 Early Drug Development and Evaluation of Putative Antitubercular Compounds in the -Omics Era
Alina Minias, Lidia Zukowska, Ewelina Lechowicz, Filip Gasior, Agnieszka Knast, Sabina Podlewska, Daria Zygala, Jaroslaw Dziadek
Frontiers in Microbiology. 2021; 11
[Pubmed]  [Google Scholar] [DOI]
12 Knowledge Gaps in the Understanding of Antimicrobial Resistance in Canada
Kayley D. McCubbin, R. Michele Anholt, Ellen de Jong, Jennifer A. Ida, Diego B. Nóbrega, John P. Kastelic, John M. Conly, Matthias Götte, Tim A. McAllister, Karin Orsel, Ian Lewis, Leland Jackson, Graham Plastow, Hans-Joachim Wieden, Kathy McCoy, Myles Leslie, Joan L. Robinson, Lorian Hardcastle, Aidan Hollis, Nicholas J. Ashbolt, Sylvia Checkley, Gregory J. Tyrrell, André G. Buret, Elissa Rennert-May, Ellen Goddard, Simon J. G. Otto, Herman W. Barkema
Frontiers in Public Health. 2021; 9
[Pubmed]  [Google Scholar] [DOI]
13 Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics
Bismillah Mubeen, Aunza Nayab Ansar, Rabia Rasool, Inam Ullah, Syed Sarim Imam, Sultan Alshehri, Mohammed M. Ghoneim, Sami I. Alzarea, Muhammad Shahid Nadeem, Imran Kazmi
Antibiotics. 2021; 10(12): 1473
[Pubmed]  [Google Scholar] [DOI]
14 A Test System for in vitro Screening Antimycobacterial Drug Candidates for MmpS5-MmpL5 Mediated Resistance
K. V. Shur, S. G. Frolova, N. I. Akimova, V. N. Danilenko, D. A. Maslov
Russian Journal of Genetics. 2021; 57(1): 114
[Pubmed]  [Google Scholar] [DOI]
15 The antimicrobial and immunomodulatory effects of Ionophores for the treatment of human infection
Gen Li, David M.P. De Oliveira, Mark J. Walker
Journal of Inorganic Biochemistry. 2021; : 111661
[Pubmed]  [Google Scholar] [DOI]
16 Efflux pumps in Mycobacterium tuberculosis and their inhibition to tackle antimicrobial resistance
Mark Laws, Peiqin Jin, Khondaker Miraz Rahman
Trends in Microbiology. 2021;
[Pubmed]  [Google Scholar] [DOI]
17 Applicability of Chromatographic Co-Elution for Antibiotic Target Identification
Sina Schäkermann, Dominik Wüllner, Abdulkadir Yayci, Andrew Emili, Julia Elisabeth Bandow
PROTEOMICS. 2021; 21(1): 2000038
[Pubmed]  [Google Scholar] [DOI]
18 Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis
Jinmeng Li, Gaoyi Yang, Qingshan Cai, Yu Wang, Yingying Xu, Ruoying Zhang, Yazhen Lang, Xinjun Cai
International Journal of Infectious Diseases. 2021; 110: 179
[Pubmed]  [Google Scholar] [DOI]
19 Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives
Elliasu Y. Salifu, Clement Agoni, Fisayo A. Olotu, Mahmoud E.S. Soliman
Computational Biology and Chemistry. 2020; 85: 107204
[Pubmed]  [Google Scholar] [DOI]
20 Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives
Tom Armstrong, Malcolm Lamont, Alice Lanne, Luke J. Alderwick, Neil R. Thomas
Bioorganic & Medicinal Chemistry. 2020; 28(22): 115744
[Pubmed]  [Google Scholar] [DOI]
21 Multitarget Approaches against Multiresistant Superbugs
Declan Alan Gray, Michaela Wenzel
ACS Infectious Diseases. 2020; 6(6): 1346
[Pubmed]  [Google Scholar] [DOI]
22 Screening of natural compounds that targets glutamate racemase of Mycobacterium tuberculosis reveals the anti-tubercular potential of flavonoids
Alka Pawar, Prakash Jha, Madhu Chopra, Uma Chaudhry, Daman Saluja
Scientific Reports. 2020; 10(1)
[Pubmed]  [Google Scholar] [DOI]
23 Two Decades of TB Drug Discovery Efforts—What Have We Learned?
Balachandra Bandodkar, Radha Krishan Shandil, Jagadeesh Bhat, Tanjore S. Balganesh
Applied Sciences. 2020; 10(16): 5704
[Pubmed]  [Google Scholar] [DOI]
24 Bedaquiline: A Mini Review
Nandhini Saravanabavan, Padmavathi Shanmuganathan, Manimekalai Kumarappan
Annals of SBV. 2020; 8(1): 2
[Pubmed]  [Google Scholar] [DOI]
25 Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development?
Sara Consalvi, Cristina Scarpecci, Mariangela Biava, Giovanna Poce
Bioorganic & Medicinal Chemistry Letters. 2019; 29(23): 126731
[Pubmed]  [Google Scholar] [DOI]
26 The Emergence of Phenolic Glycans as Virulence Factors in Mycobacterium tuberculosis
Danielle D. Barnes, Mimmi L. E. Lundahl, Ed C. Lavelle, Eoin M. Scanlan
ACS Chemical Biology. 2017; 12(8): 1969
[Pubmed]  [Google Scholar] [DOI]

 

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow